相关实验视频
Updated: Jan 17, 2026

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
9.3K
过敏原免疫治疗在患有严重过敏喘的患者中的安全性和有效性
Ana I Tabar1, Julio Delgado-Romero2, Eloína González-Mancebo3
1Department of Allergy, University Hospital of Navarra, Institute for Health Research (IDISNA), Pamplona, Spain.
Journal of asthma and allergy
|September 25, 2025
概括
过敏原免疫疗法 (AIT) 在现实实践中对严重过敏性喘是安全有效的. 这项研究显示,肺功能,生活质量有所改善,急诊次数减少,证实了AIT的说法.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 过敏原免疫疗法 (AIT) 是对轻度至中度过敏性喘的标准治疗方法.
- 关于AIT在严重喘患者的安全性和有效性的现实数据有限.
- 严重喘管理仍然具有挑战性,需要探索先进的治疗方案.
研究的目的:
- 评估AIT在严重过敏性喘中的实际安全性和有效性.
- 收集关于AIT对肺功能,生活质量和医疗保健利用的影响的证据.
- 评估AIT在患有严重喘患者中对至少一种过敏原敏感的结果.
主要方法:
- 在西班牙进行的一项回顾性研究,涉及6岁以上的患有严重喘的患者 (GEMA/GINA第5步).
- 包括对至少一种过敏原敏感的患者,在过去五年内接受了AIT.
- 评估安全性 (全身反应) 和有效性 (FeNO,FEV1,生活质量,救援药物使用,紧急访问).
主要成果:
- 包括93名患者;8.6%的患者出现了轻度至中度的全身反应,主要是在开始皮下免疫治疗时.
- 在AIT后观察到FeNO (6个月) 和FEV1 (12个月) 的显著改善.
- 生活质量得分有所提高,救援药物使用减少,急诊次数减少75.8%.
结论:
- 在常规的临床实践中,AIT对于控制良好的严重过敏喘是安全有效的.
- 现实世界的数据支持AIT在改善肺功能和减少恶化方面的好处.
- 需要进一步的前性研究来充分阐明AIT在严重喘中的有效性.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Allergic Reactions
32.0K
Overview
32.0K
Asthma-I: Introduction
3.4K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.4K
Asthma-III: Symptoms and Complications
3.3K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.3K
Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K

